abstract |
It is shown here that immune checkpoint inhibitors and CHI3L1 are synergistic. Accordingly, the invention relates to methods and compositions relating to combinatorial cancer therapies, for example, comprising a CHI3L1 inhibitor; and an inhibitor of an immune checkpoint protein. In some embodiments, the CHI3L1 inhibitor may be an antibody or an antibody reagent as described herein. |